Repligen vs Bio-Techne
Bio-Techne is the larger business, with $1.22bn of revenue in fiscal 2026 against $738m for Repligen (1.6 times as much). Repligen grew faster (16.4% against -0.4%). Bio-Techne kept more of each dollar of sales as profit: a net margin of 15.0% against 6.6%. Bio-Techne carries less debt relative to equity (9.5% against 25.7%).
| Latest fiscal year | RepligenRGEN, 2025 | Bio-TechneTECH, 2026 |
|---|---|---|
| Revenue | $738m | $1.22bn |
| Revenue growth | 16.4% | -0.4% |
| Net income | $48.9m | $182m |
| Operating margin | 7.5% | 20.7% |
| Net margin | 6.6% | 15.0% |
| Return on equity | 2.4% | 9.0% |
| Free cash flow | $93.9m | $263m |
| Cash | $566m | $265m |
| Total debt | $542m | $200m |
| Debt to equity | 25.7% | 9.5% |
| Dividend per share | — | $0.32 |
| Dividend yield | — | 0.4% |
| Share buybacks | $0 | $41.7m |
| Employees | 2,000 | 3,000 |
| Market value | $10.13bn | $11.35bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 39 (Weak) | 76 (Strong) |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 2 sales |